Giverhaug T, Loennechen T, Aarbakke J
Department of Pharmacology, Institute of Pharmacy, University of Tromsø, Norway.
Gen Pharmacol. 1999 Oct;33(4):341-6. doi: 10.1016/s0306-3623(99)00022-1.
The antimetabolites 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of children's acute lymphoblastic leukemia (ALL). The biochemical mechanisms underlying the increased therapeutic efficacy of the combination of these drugs have not yet been elucidated. However, both drugs interact with important pathways. such as purine de novo synthesis (PDNS), purine salvage, and methylation reactions. A review of the mechanistic aspects of the interactions between 6-MP and MTX is given.
抗代谢药物6-巯基嘌呤（6-MP）和甲氨蝶呤（MTX）是儿童急性淋巴细胞白血病（ALL）维持治疗的基石。这两种药物联合使用时疗效增加的生化机制尚未阐明。然而，这两种药物均与重要途径相互作用，如嘌呤从头合成（PDNS）、嘌呤补救途径和甲基化反应。本文对6-MP与MTX相互作用的机制方面进行了综述。
